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Background & aims
The Medicines and Healthcare Regulatory Authority
(MHRA) in the UK runs a national spontaneous report-
ing system (Yellow Card Scheme) to collect ‘suspected’
Adverse Drug Reactions (ADRs) for all medicines. To
increase the data for paediatric medicines, current
MHRA advice is to report all suspected ADRs in paedia-
tric patients. Yellow Cards submitted between 2000 and
2009 were analysed for medications commonly used in
paediatric rheumatology.
Methods
Data on all UK spontaneous ‘suspected’ ADRs reported
to the MHRA in patients <17 years from the years 2000-
9 were supplied. Data included age, type of reaction,
medication and type of reporter, but were unlinked. Data
were only supplied on an individual drug if five or more
suspected ADRs were reported in a calendar year. The
cut-off values in the data supplied were in accordance
with policy guidelines applied by the MHRA to preserve
confidentiality of reporters and patients.
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Table 1
Drug 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Total
ALEMTUZUMAB 92 2 31
AZATHIOPRINE 6 8 14
CYCLOPHOSPHAMIDE 11 18 36 65
CYCLOSPORIN 6 6 6 9 9 25 59 120
ETANERCEPT 8 8 22 22 20 14 94
ETOPOSIDE 5712
INFLIXIMAB 5 7 10 5 10 11 20 68
METHOTREXATE 6 5981 6 1 1 1 3 3 9 4 0 147
MYCOPHENOLIC ACID 8 8
PREDNISOLONE 6 12 14 19 51
RITUXIMAB 7512
TACROLIMUS 8 12 7 10 13 12 7 18 87
Hawcutt et al. Pediatric Rheumatology 2011, 9(Suppl 1):P237
http://www.ped-rheum.com/content/9/S1/P237
© 2011 Hawcutt et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Results
The number of reports of suspected ADRs to drugs
commonly used in paediatric rheumatology per year are
shown in Table 1. Adalimumab, tocilzumab & abatacept
did not generate sufficient reports to feature in the data-
set. There has been an increase in reporting over the 10
year period, with a median of 17 (2000-2) increasing to
a median of 148 (2007-9). This increase is greater than
the overall increase in reporting seen in the period
(Hawcutt et al, submitted). However, the unlinked nat-
ure of the data supplied means that it is not possible to
ascertain if the medications were prescribed in paedia-
tric rheumatology patients.
Conclusions
Medications commonly used in paediatric rheumatology
generate suspected ADR reports in the UK. The overall
reporting rate appears to be increasing, but reporting of
biologics is lower than expected
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